[Autom. eng. transl.] Ingenolo mebutato, summarizing the organizational and managerial advantages of topical therapies and outpatient treatments, in the face of a real and significant efficacy of the product, appears as an important therapeutic alternative for the treatment of AK, also in favor of categories of patients for whom other therapeutic solutions could be complex to implement, with a consequent reduction in the adherence and effectiveness of the treatment itself.
|Translated title of the contribution||[Autom. eng. transl.] Analysis of the organizational consequences of the introduction of Ingenolo mebutato in the specific Italian treatment context, in Evaluation of the clinical, economic, ethical and organizational impact of the introduction of a new health technology, Ingenolo Mebutato, in the treatment of actinic keratosis in Italy|
|Number of pages||12|
|Publication status||Published - 2013|
- Actinic keratosis
- Ingenol mebutate
- health technology assessment
- organisational impact